BioProtect Establishes a New Subsidiary in Germany
BioProtect, Ltd, a leader in balloon spacers for radiation oncology , has established a new subsidiary in Germany called BioProtect GmbH, a company that is duly incorporated with offices located in the city of Hamburg
This new subsidiary will help BioProtect expand in a large country that recently established a reimbursement code OPS-code 5-609-91 related to the spacer implantation procedure for the prevention of rectal toxicity among prostate cancer patients who receive radiation therapy.
Mr. Manfred Koch was appointed general manager of the subsidiary. Sales, service and logistics personnel were hired as well.
Mr. Koch has over 25 years of experience in leading sales and marketing organizations in the medical arena (Olympus Optical, Haemonetics, Augustine Medical, Terumo, Embla, Swiss Medical). He has lived and worked in the US, France, Netherlands, Switzerland and his home country Germany. He has managed direct operations as well as B2B sales in Europe, Asia, South America, Canada and the PAC Rim, with full P&L responsibility. In the past 18 years Mr. Koch has been focusing on establishing organizations in startup companies.
“We are pleased to welcome Mister Koch to our company, as his experience and knowledge of the oncology market will lead to the success of BioProtect GmbH,” said Israel Birenbaum, CEO of BioProtect. “The German healthcare market is one of the most advanced in the world, therefore it’s an important market for us.”
AG Hamburg, HRB 148889
Herr Manfred Koch, Geschäftsleiter
Unterberg 19 b 21033 Hamburg